BEAT-LUPUS: Sequential Belimumab After Rituximab in SLE
Oct 27, 2021
Recent News
Read ArticleThe Annals of Internal Medicine reports that targeting B-cells in refractory systemic lupus erythematosus (SLE) with sequential belimumab after rituximab may significantly reduce dsDNA antibody titers and lessen the number of future severe flares.
Biologics Use and the Risk of Serious Infection in Psoriasis Patients
Oct 28, 2021
National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremilast). Risk of serious infections was not increased for new users of secukinumab, ixekizumab, brodalumab, guselkumab, or apremilast vs etanercept, b
Read Article
The Sacroiliac Joint - some call this a symphysis, but it is an "amphiarthrosis", or sliding joint, with minimal movement; Only the lower (distal) 1/3 of the joint is synovial lined -- this is where one should look for sacroiliitis. https://t.co/8uD13h2qHZ https://t.co/D3UERVXrgX https://t.co/3E3N1FnqDY
Dr. John Cush @RheumNow ( View Tweet)
Oct 28, 2021
FDA put a box warnings on breast implant packaging to include info that 1)Breast implants are not lifetime devices; 2) complication risk increases over time; 3) risk of anaplastic large cell lymphoma, 4) may be assoc w/ systemic Sxs https://t.co/VnpJg45PZY
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 28, 2021
Rheumatoid Arthritis Thrombotic Risk Influenced by DMARD Choice
https://t.co/gOLhO2aNOo https://t.co/FwKP3slExA
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 28, 2021
QD Clinic - The Thyroid Lump
QD Clinic is sponsored by https://t.co/V10S4oE43V's coverage of #ACR21
https://t.co/J5YkJmaNea https://t.co/UidG4dT1JJ
Dr. John Cush @RheumNow ( View Tweet)
Oct 28, 2021
Rheumatoid Arthritis Thrombotic Risk Influenced by DMARD Choice
Oct 27, 2021
RA patients have an increased risk of venous thromboembolism (VTE) related to disease activity and inflammation, yet a large real-world study of older RA patients shows methotrexate to be associated with a 2-fold increased VTE risk (compared to hydroxychloroquine).
Read Article
Platelet-Rich Plasma Injections Fail in Ankle Osteoarthritis
Oct 27, 2021
A controlled trial of intra-articular platelet-rich plasma (PRP) injections into the ankle of osteoarthritis (OA) patients failed to improve ankle symptoms and function when compared to placebo injections - yet another trial showing that intraarticular injections are seldom beneficial.
Read Article
Platelet-Rich Plasma Injections Fail in Ankle Osteoarthritis
https://t.co/Fmf8f2C3Y4 https://t.co/9ZJe2jAYVw
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2021
Sign up today to receive #ACR21 news and select topic emails throughout the conference. #RheumNow
https://t.co/riyAnrRHhX https://t.co/MkoDsw34D0
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2021
While psoriasis and Psoriatic arthritis patients have an increased risk of fractures, there is no increased risk of osteoporosis or osteopenia. Data from 12 studies an 199 million individuals https://t.co/G4Ya7CUWYX
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2021
Systematic review of dsDNA studies (byfluorescence immunoassay) included 1977 total patients, 47% with SLE == over all dsDNA had >90% for specificity and a pooled specificity of 94.7% (95% CI 91.67%-96.67%) https://t.co/Nk8h9fDYpE
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2021
Methotrexate is the most often-studied treatment and has best clinical outcomes in children and adults with localized scleroderma en coup de sabre. Metanalysis of 34 articles, only 4 RCTs, but 24 case reports. More research needed. https://t.co/fSEvDw2pge
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 27, 2021
Pfizer/Lilly Pull Tanezumab Development
Oct 26, 2021
Today, Lilly and Pfizer announced their global clinical development of the NGF inhibitor, tanezumab, has been discontinued due to recent negative opinions from the EMA and FDA advisory committee.
This decision mirrors that of other companies (AbbVie, AstraZeneca, Johnson & Johnson) who, in the last 10 years, have halted NGF inhibitor development due to FDA concerns over risk/benefit in patients with osteoarthritis.
Read Article
Register now to receive #ACR21 news and select topic emails throughout the conference.
https://t.co/riyAnrRHhX https://t.co/ufGxXnbtoG
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
Rheumatic pts admitted to ICU, #SLE is most common & Sepsis most common reason. 80 ARD pts adm to ICU: Dx were SLE (42%), RA (26%), vasculitis (12%) FOR Sepsis (31%), (10%) CHF (10%). 20% died in ICU, 5% 30d after ICU, 7.5% w/in 1 yr https://t.co/lX0m3vOukI
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
Short (3 min) walks intstead of sitting benefits RA w/ anticytokine effect (TNF, IL1RA), improved glucose, c-peptide, insulin. Crossover study 15 RA women who had 1) prolonged sitting, 2) 30-min mod-vigor exercise or 3) 3-min of light walking every 30 min https://t.co/36AnhHL9OI
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
New Download Available!
FDA EUA for Baricitinib in COVID
https://t.co/yTQLb7DDvR https://t.co/n9Npg0Pq5q
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
Watch: QD Clinic - Severe Arthritis Numbers
QD Videos are brought to you by RheumNow's upcoming coverage of ACR 2021
https://t.co/QgBL4dnCk7
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
From March to Dec 2020, study of 116K COVID pts saw monthly rates of hospitalization (105/100K), ICU admits (20/100K), & death (12/100K) -peaked 12/20. Highest w/ age >65yrs, hispanics, blacks. Remdesivir incr 1.7% to 54%; Steroids 19% to 74.2% https://t.co/5pzu74YIz6
Links:
Dr. John Cush @RheumNow ( View Tweet)
Oct 26, 2021
New Hope for NonAlcoholic Fatty Liver Disease
Oct 25, 2021
The current issue of the NEJM has two articles on nonalcoholic fatty liver disease (NAFLD also called NASH - nonalcoholic steatohepatitis), one dealing with the prognoses, outcomes and mortality of NAFLD and another prospective and promising interventional trial in NASH patients.
Read Article
From the blog
ICYMI: Steroid Poker
Oct 20, 2021
It began as many cases do: an ill patient, in the ICU, with signs and symptoms across several body systems, yet no clear unifying diagnosis on admission. With things stabilizing, the internal medicine hospital team on which I was serving as hospitalist that week assumed care of the patient. As the case unfolded – pulmonary infiltrates that could be hemorrhagic, renal dysfunction with proteinuria – rheumatic diseases rose in the differential. When serologic studies and other data suggested GPA rather than glomerular basement membrane (GBM) disease or other possibilities such as infection, it seemed the right time to act. And that is when a game of what I call “steroid poker” began.
Read Post
Recent Podcasts
- RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)Oct 22, 2021
- RheumNow Podcast – Quackademia (10.15.2021)Oct 15, 2021
- RheumNow Podcast – Quackademia (10.15.2021)Oct 15, 2021
- RheumNow Podcast – #ACA Ask Cush Anything (10.8.2021)Oct 08, 2021
- RheumNow Podcast – Jack of All Subspecialties (10.1.2021)Oct 01, 2021
Therapeutic Update
Upadacitinib in Difficult-to-Treat Patients With RA
Sponsored by AbbVie Medical Affairs
Oct 01, 2021
Treatment goals can be challenging for those with RA who are bDMARD-IR. Hear Dr. Tesser’s approach and learn about SELECT-BEYOND and SELECT-CHOICE, where upadacitinib was assessed in such patients.
Read Post
